Want to see SKYE full AI Analyst Report?
SKYE Stock Chart & Stats
$2.02
-$0.02(-3.42%)
At close: 4:00 PM EDT
$2.02
-$0.02(-3.42%)
Day’s Range― - ―
52-Week Range$1.50 - $39.92
Previous CloseN/A
Volume45.97K
Average Volume (3M)79.82K
Market Cap
$7.44M
Enterprise Value$17.63M
Total Cash (Recent Filing)$10.06M
Total Debt (Recent Filing)$35.70K
Price to Earnings (P/E)―
Beta3.49
Next Earnings
Nov 05, 2026EPS Estimate
-1.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.16
Shares Outstanding4,427,676
10 Day Avg. Volume66,825
30 Day Avg. Volume79,816
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.49
Price to Sales (P/S)0.00
P/FCF Ratio-0.69
Enterprise Value/Market Cap2.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-102.00
Enterprise Value/Ebitda-0.35
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-7.22
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Absolute DebtVery low absolute debt limits interest and refinancing pressure, preserving more flexibility for research spending and strategic execution. Although the balance sheet remains weak overall, the absence of substantial borrowings reduces the risk that creditors will compete with development programs for scarce cash over the next several quarters.
Significant Development FundingThe planned financing package provides a meaningful source of development capital and is intended to fund operations into 2029. That runway can support clinical execution and milestone delivery without relying solely on near-term fundraising, although the equity structure still carries potential dilution for existing holders.
Expanded Fibrosis PipelineThe proposed Redx combination would add a Phase 2 lead asset and broader fibrosis programs to Skye's platform, creating a more diversified clinical pipeline. RXC008's Fast Track status and focus on fibrostenotic Crohn's disease could support regulatory engagement in an area described as having high unmet need.
Bears Say
Pre-revenue Losses Are WideningSkye has no commercial revenue to offset development costs, while its TTM net loss is substantially wider than in 2024. This combination leaves earnings dependent on future clinical and commercial success, and the worsening loss profile increases the amount of capital required before the business can become self-sustaining.
Severe Cash Burn And Negative EquityPersistent operating and free-cash-flow deficits show that reported losses are translating into substantial cash consumption. Combined with negative equity and declining assets, this weakens the capital cushion and increases reliance on external financing, creating ongoing funding and dilution pressure as programs advance.
Nasdaq Compliance And Delisting RiskThe Nasdaq equity deficiency creates a structural financing and execution overhang because Skye must restore compliance or obtain additional relief while pursuing its strategic plans. Failure to remediate could threaten continued listing, complicate capital access, and increase uncertainty around the Redx transaction.
Skye Bioscience News
SKYE FAQ
What was Skye Bioscience’s price range in the past 12 months?
Skye Bioscience lowest stock price was $1.50 and its highest was $39.92 in the past 12 months.
What is Skye Bioscience’s market cap?
Skye Bioscience’s market cap is $7.44M.
When is Skye Bioscience’s upcoming earnings report date?
Skye Bioscience’s upcoming earnings report date is Nov 05, 2026 which is in 31 days.
How were Skye Bioscience’s earnings last quarter?
Skye Bioscience released its earnings results on Aug 14, 2026. The company reported -$2.16 earnings per share for the quarter, missing the consensus estimate of -$2.04 by -$0.12.
Is Skye Bioscience overvalued?
According to Wall Street analysts Skye Bioscience’s price is currently Overvalued.
Does Skye Bioscience pay dividends?
Skye Bioscience does not currently pay dividends.
What is Skye Bioscience’s EPS estimate?
Skye Bioscience’s EPS estimate is -1.14.
How many shares outstanding does Skye Bioscience have?
Skye Bioscience has 4,427,676 shares outstanding.
What happened to Skye Bioscience’s price movement after its last earnings report?
Skye Bioscience reported an EPS of -$2.16 in its last earnings report, missing expectations of -$2.04. Following the earnings report the stock price went down -7.301%.
Which hedge fund is a major shareholder of Skye Bioscience?
Currently, no hedge funds are holding shares in SKYE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Skye Bioscience
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Technical Analysis
Ownership Overview
60.61% Insiders
2.67% Mutual Funds
6.38% Other Institutional Investors
28.21% Public Companies and
Individual Investors